| Analysis | Metabolite Name | Measured Value | Units | Model | Intervention |
|---|---|---|---|---|---|
| Normal phase UNSPECIFIED ION MODE | Pyridoxamine | 0.0000072 | peak area | Wild type | Saline |
| Normal phase UNSPECIFIED ION MODE | Pyridoxamine | 0.000011 | peak area | Wild type | B. breve MCC1274 |
| Normal phase UNSPECIFIED ION MODE | Pyridoxamine | 0.000011 | peak area | Wild type | Saline |
| Normal phase UNSPECIFIED ION MODE | Pyridoxamine | 0.000012 | peak area | Alzheimer’s disease model | Saline |
| Normal phase UNSPECIFIED ION MODE | Pyridoxamine | 0.000017 | peak area | Alzheimer’s disease model | B. breve MCC1274 |
| Normal phase UNSPECIFIED ION MODE | Pyridoxamine | 0.000021 | peak area | Alzheimer’s disease model | Saline |
| Normal phase UNSPECIFIED ION MODE | Pyridoxamine | 0.000022 | peak area | Wild type | B. breve MCC1274 |
| Normal phase UNSPECIFIED ION MODE | Pyridoxamine | peak area | Alzheimer’s disease model | B. breve MCC1274 | |
| Normal phase UNSPECIFIED ION MODE | Pyridoxamine | peak area | Alzheimer’s disease model | Saline | |
| Normal phase UNSPECIFIED ION MODE | Pyridoxamine | peak area | Wild type | B. breve MCC1274 | |
| Normal phase UNSPECIFIED ION MODE | Pyridoxamine | peak area | Wild type | Saline |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|